IW 308

September 28, 2025 Viktor Zarev 0 min read
  1. Trump administration plans 100% tariff on imported drugs.
  2. FDA to launch safety review of abortion pill.
  3. ACA subsidy expiration could cost hospitals $32B.
  4. Medicare Advantage firms laud RADV court ruling.
  5. PBMs hope to head off reform efforts.
  6. GAO report probes costs of Georgia’s Medicare work rule.
  7. CommonSpirit cuts fiscal 2025 operating loss to $225M.
  8. FDA approves eyeglass lenses for nearsighted kids.
  9. Huntington’s disease treated for first time. 
  10. New obesity drug could work better than GLP-1s.
Get twice-weekly insights on the biggest stories shaping cardiology.

You might also like

Cardiology Business January 15, 2026

FTC Wins Lawsuit Against Edwards Over JenaValve January 15, 2026

Following a six-month antitrust fight, Edwards Lifesciences has been forced to walk away from its $945M attempt to buy fledgling valve developer JenaValve after a U.S. district court ruled in favor of the FTC’s decision to block the move. The FTC’s big issue didn’t just start Edwards acquiring JenaValve, rather it was the short timespan […]

Cardiogenetics January 12, 2026

Y Chromosome Loss and MI Risk January 12, 2026

We already know that loss or mutation in genes can lead to increased cardiovascular risk or even cause some diseases, but what about losing a whole chromosome? New research in JACC suggests that men who lose pieces of their Y chromosome as they age could be at greater risk of heart attacks. Researchers measured the […]

Cardiology Testing January 8, 2026

HF Frailty Could Be Simpler than We Think January 8, 2026

A new registry analysis out of Japan suggests we may be able to simplify how we classify heart failure frailty without losing accuracy, allowing us to screen for HF mortality risk in faster and more practical ways. To see how CFS stacks up against comprehensive physical testing, researchers categorized 3.9k patients hospitalized with HF into […]